OVARIAN CLEAR CELL ADENOCARCINOMA
Clinical trials for OVARIAN CLEAR CELL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CLEAR CELL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN CLEAR CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a less invasive surgery help ovarian cancer patients live longer and better?
Disease control Recruiting nowThis study tests if a less invasive surgery (laparoscopy) works as well as or better than standard open surgery for people with advanced ovarian, fallopian tube, or peritoneal cancer who have already had chemotherapy. About 580 participants will be randomly assigned to one of the…
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:03 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase study tests a combination of two experimental drugs (M1774 and ZEN-3694) in people whose ovarian or endometrial cancer has returned after previous treatment. The goal is to find the safest dose and see how well the drugs work together to stop cancer cell growth. …
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:03 UTC
-
Promising combo therapy targets fluid buildup in recurrent ovarian cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control fluid buildup and tumor growth in people whose ovarian, fallopian tube, or peritoneal cancer has returned. About 60 ad…
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for recurrent ovarian cancer: triple drug attack launched
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with specific types of recurrent ovarian, fallopian tube, or peritoneal c…
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:50 UTC